Early research (Phase 1)Study completedNCT02315612
What this trial is testing
Anti-CD22 Chimeric Receptor T Cells in Pediatric and Young Adults With Recurrent or Refractory CD22-expressing B Cell Malignancies
Who this might be right for
NHLLarge Cell LymphomaFollicular Lymphoma+7 more
National Cancer Institute (NCI) 134